Champions Oncology Inc
NASDAQ:CSBR

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
NASDAQ:CSBR
Watchlist
Price: 4.7 USD -0.63% Market Closed
Updated: May 19, 2024

Champions Oncology Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Champions Oncology Inc
Cost of Revenue Peer Comparison

Comparables:
TMO
DHR
MTD
A
IQV

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Champions Oncology Inc
NASDAQ:CSBR
Cost of Revenue
-$29.5m
CAGR 3-Years
-13%
CAGR 5-Years
-18%
CAGR 10-Years
-22%
Thermo Fisher Scientific Inc
NYSE:TMO
Cost of Revenue
-$25.3B
CAGR 3-Years
-13%
CAGR 5-Years
-13%
CAGR 10-Years
-12%
Danaher Corp
NYSE:DHR
Cost of Revenue
-$18.2B
CAGR 3-Years
-20%
CAGR 5-Years
-20%
CAGR 10-Years
-7%
Mettler-Toledo International Inc
NYSE:MTD
Cost of Revenue
-$1.5B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
Agilent Technologies Inc
NYSE:A
Cost of Revenue
-$3.3B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
IQVIA Holdings Inc
NYSE:IQV
Cost of Revenue
-$9.7B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-10%

See Also

What is Champions Oncology Inc's Cost of Revenue?
Cost of Revenue
-29.5m USD

Based on the financial report for Jan 31, 2024, Champions Oncology Inc's Cost of Revenue amounts to -29.5m USD.

What is Champions Oncology Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-22%

Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for Champions Oncology Inc have been -13% over the past three years , -18% over the past five years , and -22% over the past ten years .